Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Capecitabine and Radiation in Rectal Cancer
NCT00122291Phase 2Unknown
- Sponsor
- Alberta Health Services
- Start
- Jan 2002
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Alberta Health Services. Primary endpoints: Safety and Response. Status: unknown.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00122291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122291.